Lineage Partners with William Demant Invest to Advance ReSonance™ (ANP1) for Hearing Loss Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2025
0mins
Source: Newsfilter
Collaboration Announcement: Lineage Cell Therapeutics has partnered with William Demant Invest to advance the preclinical development of its auditory neuronal cell transplant, ReSonance (ANP1), aimed at treating hearing loss.
Funding Details: William Demant Invest will contribute up to $12 million for research collaboration costs, which will support various preclinical activities including cell manufacturing and regulatory strategy.
Significance of Hearing Loss: The World Health Organization predicts that nearly 2.5 billion people will experience some degree of hearing loss by 2025, highlighting the urgent need for effective treatments like cell-based therapy.
Company Backgrounds: Lineage Cell Therapeutics focuses on developing novel cell therapies for unmet medical needs, while William Demant Invest is an evergreen investor linked to a leading hearing healthcare company, emphasizing their commitment to advancing hearing health solutions.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like LCTX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on LCTX
Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 4.50 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.580
Low
3.00
Averages
4.50
High
9.00
Current: 1.580
Low
3.00
Averages
4.50
High
9.00
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
Continue Reading
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
- Market Transformation: The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations (CDMOs) capturing 67.5% market share, marking a transition from boutique R&D to scalable bioprocessing infrastructure that accelerates industry growth.
- Surging Demand: The demand for gene and CAR-T therapies has driven CDMO partnerships to rapidly expand viral vector production and GMP-compliant facilities, overcoming previous bottlenecks that constrained commercial access, significantly enhancing market entry speed.
- Investment Opportunity: The regenerative medicine market is projected to surge from $48.45 billion in 2024 to $403.86 billion by 2032, with cell-based therapies representing the fastest-growing segment, creating an urgent investment window, especially as emerging biotechs trade at steep discounts.
- Technological Innovation: Avant Technologies is advancing cell encapsulation technology through its joint venture Insulinova with SGAustria, aiming to provide effective long-term treatments for diabetes patients globally, addressing the immune rejection of implanted cells, thereby significantly improving patients' quality of life.
Continue Reading